Compound interaction — running MOTS-c and reta concurrently, any concerns

No obvious conflict. The glucagon arm of reta can raise hepatic glucose output mildly, MOTS-c improves peripheral IS, they probably compose cleanly. Watch fasting glucose though — I've seen reta cause brief AM glucose bumps in some users.

MOTS-c synergizes well with GLP-1 class in theory — parallel improvements in IS, FGF21-like metabolic effects. No AE reports I've seen in forum history.

Isolate variables concern applies but for an experienced stacker running both, probably fine. Just track the usual: fasting glucose, insulin, HbA1c at baseline and week 12.

No literature on the combo. Theoretical synergy only. Track carefully and report back — this is a data-generating combo.

Lipase at baseline and week 6 too — reta is a GLP-1 class compound, pancreatic safety markers are cheap and worth watching.

Good notes. Will track fasting glucose, insulin, HbA1c, lipase/amylase at baseline and 6/12. Will report back.

@dr_doubt acknowledged. My priority is outcome, not attribution, this cycle. Attribution will come from serial cycles with different lead compounds.

The theoretical synergy is real but remember that running both doubles your attribution problem. If markers move great, which compound gets credit? For efficacy you might never know.

NAD+ pairs well with MOTS-c on the mitochondrial side. Consider adding if you're going deep on the metabolic angle.